Wednesday, February 10, 2010, 6:46am EST - Canadian Markets open in 2 hours and 44 minutes.
To create a watchlist or portfolio of shares, Sign-in or Register

AEterna Zentaris Inc. (AEZS)

On Feb 9: 0.82 USD   0.00 (0.00%)  
MORE ON AEZS
Quotes
Charts
News & Info
HereHeadlines
Company
Analyst Coverage
Ownership
Financials
Headlines Get Headlines for:
Wed, Feb 3, 2010
AEterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of
PRNewswire (Wed, Feb 3)
Æterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of
CNW Group (Wed, Feb 3)
Æterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer
PR Newswire (Wed, Feb 3)
Fri, Jan 29, 2010
Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom's Macroglo
CNW Group (Fri, Jan 29)
AEterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom's Macrogl
PRNewswire (Fri, Jan 29)
Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom's Macroglobulinemia
PR Newswire (Fri, Jan 29)
Keryx Biopharmaceuticals Announces Positive Phase 2 Study Results of Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom's Macroglo
PRNewswire (Fri, Jan 29)
Biotech Stock Mailbag: Keryx Biopharmaceuticals
at TheStreet.com (Fri, Jan 29)
Wed, Jan 27, 2010
Keryx Biopharmaceuticals, Inc. to Conduct Conference Call to Discuss KRX-0401 (Perifosine) Clinical Development Program in Colorectal Cancer
PRNewswire (Wed, Jan 27)
UPDATE - Spectrum to end development of enlarged-prostate drug
at Reuters (Wed, Jan 27)
Tue, Jan 26, 2010
Liberty Analytics Co. Initiates Independent Research Coverage on AEterna Zentaris Inc.
GlobeNewswire (Tue, Jan 26)
Mon, Jan 25, 2010
Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Cont
CNW Group (Mon, Jan 25)
AEterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Con
PRNewswire (Mon, Jan 25)
Keryx Reports Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of KR
PRNewswire (Mon, Jan 25)
Fri, Jan 22, 2010
AEterna Zentaris Receives NASDAQ Notification Related to Minimum Bid Price
PRNewswire (Fri, Jan 22)
Æterna Zentaris Receives NASDAQ Notification Related to Minimum Bid Price
CNW Group (Fri, Jan 22)
Thu, Jan 21, 2010
AEterna Zentaris Partner, Keryx Biopharmaceuticals, to Present Poster Highlighting Clinical Activity of Perifosine (KRX-0401) at the ASCO 2010 Gastroi
PRNewswire (Thu, Jan 21)
Æterna Zentaris Partner, Keryx Biopharmaceuticals, to Present Poster Highlighting Clinical Activity of Perifosine (KRX-0401) at the ASCO 2010 Gastroin
CNW Group (Thu, Jan 21)
Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the ASCO 2010 Gastrointestinal Cance
PRNewswire (Thu, Jan 21)
Mon, Dec 21, 2009
The Complete List of Canadian Stocks Traded on the Nasdaq
at Seeking Alpha (Mon, Dec 21)
Sun, Dec 20, 2009
This Week's Failed Trials, Missed Targets in Biotech
at Seeking Alpha (Sun, Dec 20)
Fri, Dec 18, 2009
Æterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Beni
CNW Group (Fri, Dec 18)
Older Headlines
View headlines from:

Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Headlines for Another Symbol:
Symbol Lookup
Latest News Canadian Indices